TY - JOUR
T1 - A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol
AU - Fulton, D.
AU - Falck, J. R.
AU - McGiff, J. C.
AU - Carroll, M. A.
AU - Quilley, J.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998/8
Y1 - 1998/8
N2 - The 5,6 epoxyeicosatrienoic acid (5,6-EET) exhibits a range of biological activities but the functional significance of this labile eicosanoid is unknown due, in part, to difficulties of quantitation in biological samples. We have developed a sensitive and specific method to measure 5,6-EET utilizing its selective capacity to form a lactone. The initial conversion of 5,6-EET and 5,6-dihydroxyeicosatrienoic acid (5,6-DHT) to 5,6-δ-lactone is followed by selective purification using reverse phase high performance liquid chromatography (HPLC), reconversion to 5,6-DHT and quantitation by gas chromatography-mass spectrometry (GCMS). In oxygenated Krebs' buffer, 5,6-EET degrades to 5,6-δ-lactone and 5,6-DHT with a t(1/2) ≃ 8 min. In the presence of camphorsulfonic acid, 5,6-EET and 5,6-DHT convert to a single HPLC peak (λ = 205) comigrating with 5,6-δ-lactone. Incubation of 5,6-δ-lactone with triethylamine resulted in a single HPLC peak with the retention time of 5,6-DHT. In the perfusate from the isolated kidney, release of 5,6-EET (20 ± 5 pg/ml), measured indirectly via conversion to 5,6-DHT, was approx. 6-fold less than that reported for prostaglandin E2 (PGE2) and 20-HETE. The coronary perfusate concentration of 5,6 EET was 9 ± 2 pg/ml. 5,6-EET recovered from renal and coronary perfusates was increased 2-fold to 45.5 ± 5.5 pg/ml and 21.6 ± 6.3 pg/ml, respectively, by arachidonic acid.
AB - The 5,6 epoxyeicosatrienoic acid (5,6-EET) exhibits a range of biological activities but the functional significance of this labile eicosanoid is unknown due, in part, to difficulties of quantitation in biological samples. We have developed a sensitive and specific method to measure 5,6-EET utilizing its selective capacity to form a lactone. The initial conversion of 5,6-EET and 5,6-dihydroxyeicosatrienoic acid (5,6-DHT) to 5,6-δ-lactone is followed by selective purification using reverse phase high performance liquid chromatography (HPLC), reconversion to 5,6-DHT and quantitation by gas chromatography-mass spectrometry (GCMS). In oxygenated Krebs' buffer, 5,6-EET degrades to 5,6-δ-lactone and 5,6-DHT with a t(1/2) ≃ 8 min. In the presence of camphorsulfonic acid, 5,6-EET and 5,6-DHT convert to a single HPLC peak (λ = 205) comigrating with 5,6-δ-lactone. Incubation of 5,6-δ-lactone with triethylamine resulted in a single HPLC peak with the retention time of 5,6-DHT. In the perfusate from the isolated kidney, release of 5,6-EET (20 ± 5 pg/ml), measured indirectly via conversion to 5,6-DHT, was approx. 6-fold less than that reported for prostaglandin E2 (PGE2) and 20-HETE. The coronary perfusate concentration of 5,6 EET was 9 ± 2 pg/ml. 5,6-EET recovered from renal and coronary perfusates was increased 2-fold to 45.5 ± 5.5 pg/ml and 21.6 ± 6.3 pg/ml, respectively, by arachidonic acid.
KW - 5,6-DHT
KW - 5,6-EET
KW - 5,6-δ-lactone
KW - GC-MS
KW - Heart
KW - Kidney
UR - http://www.scopus.com/inward/record.url?scp=0031822225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031822225&partnerID=8YFLogxK
M3 - Article
C2 - 9717733
AN - SCOPUS:0031822225
SN - 0022-2275
VL - 39
SP - 1713
EP - 1721
JO - Journal of lipid research
JF - Journal of lipid research
IS - 8
ER -